Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMMU

Immunomedics (IMMU) Stock Price, News & Analysis

Immunomedics logo

About Immunomedics Stock (NASDAQ:IMMU)

Advanced Chart

Key Stats

Today's Range
$87.86
$87.86
50-Day Range
$85.08
$87.86
52-Week Range
$8.80
$87.93
Volume
N/A
Average Volume
4.01 million shs
Market Capitalization
$20.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IMMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

IMMU Stock News Headlines

Gilead Sciences Tops Estimates in Q3
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
Gilead Sciences Shows Strong Q3 Results Amid Strategic Initiatives
See More Headlines

IMMU Stock Analysis - Frequently Asked Questions

Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to the consensus estimate of $24.81 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Gilead Sciences (GILD) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2020
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMMU
CIK
722830
Fax
N/A
Employees
366
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$357.19 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-132.40%
Return on Assets
-51.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.84
Quick Ratio
12.58

Sales & Book Value

Annual Sales
$290 thousand
Price / Sales
70,028.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.38 per share
Price / Book
63.67

Miscellaneous

Outstanding Shares
231,144,000
Free Float
N/A
Market Cap
$20.31 billion
Optionable
Optionable
Beta
2.90
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IMMU) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners